Moreover, MIF ameliorates the symptoms of NASH and fibrosis via the CD74/AMPK pathway, which is shown by reduced accumulation of inflammation-related and oleic acid-elicited triglyceride. Here, PRKAA2 is linked to metabolic dysfunction-associated steatohepatitis.